Dimensional Fund Advisors LP Verastem, Inc. Transaction History

Dimensional Fund Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.39 - $0.71 $24,750 - $45,058	-63,463 Reduced 12.04%	463,751 $194,000
Q4 2022 Feb 09, 2023	SELL	$0.33 - $10.44 $63,551 - $2.01 Million	-192,581 Reduced 26.75%	527,214 $210,000
Q3 2022 Nov 10, 2022	SELL	$0.92 - $11.16 $595,475 - $7.22 Million	-647,256 Reduced 47.35%	719,795 $612,000
Q2 2022 Aug 12, 2022	SELL	$1.02 - $1.83 $502,760 - $902,010	-492,902 Reduced 26.5%	1,367,051 $1.59 Million
Q1 2022 May 13, 2022	SELL	$1.06 - $2.1 $588,163 - $1.17 Million	-554,871 Reduced 22.98%	1,859,953 $2.62 Million
Q4 2021 Feb 09, 2022	BUY	$2.05 - $3.2 $273,246 - $426,531	133,291 Added 5.84%	2,414,824 $4.95 Million
Q3 2021 Nov 12, 2021	BUY	$2.54 - $4.07 $1.19 Million - $1.91 Million	469,373 Added 25.9%	2,281,533 $7.03 Million
Q2 2021 Aug 12, 2021	BUY	$2.57 - $4.85 $1.6 Million - $3.01 Million	620,670 Added 52.09%	1,812,160 $7.38 Million
Q1 2021 May 14, 2021	BUY	$1.9 - $2.82 $1.58 Million - $2.34 Million	830,556 Added 230.11%	1,191,490 $2.94 Million
Q4 2020 Feb 25, 2021	BUY	$1.15 - $2.4 $415,074 - $866,241	360,934 New	360,934 $769,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.2B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.